ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increasing Over Time ANX005 Beneficial Impact Larger in Patients with North American and European Baseline Characteristics Across Key Measures of Disability and Muscle Strength Single Infusion of ANX005 was Generally Well-Toler ...

文章核心观点 - 公司的C1q靶向免疫治疗药物ANX005在治疗重症格林-巴利综合征(GBS)的III期临床试验中取得积极成果 [1][2][3] - ANX005能够快速抑制神经炎症,显著改善多个终点指标,使患者恢复更快更完全 [2][3] - 与安慰剂相比,ANX005治疗组有更多患者在26周内恢复到正常/治疗前健康状态 [3] - 对于具有北美和欧洲基线特征的患者,ANX005的治疗效果更加显著 [4][5] - ANX005单次输注总体耐受性良好,安全性与安慰剂相似 [3][6] - 这些结果证实了ANX005作为首个针对性免疫治疗GBS的潜力 [3][6] 根据目录分别总结 GBS-Disability Scale (GBS-DS) - 第8周时,ANX005组患者处于更好健康状态的可能性是安慰剂组的2.41倍 [3] - 第1周时,ANX005组患者处于更好健康状态的可能性是安慰剂组的7.22倍 [3] - 第4周时,ANX005组患者处于更好健康状态的可能性是安慰剂组的2.49倍 [3] - 第26周时,ANX005组有2.5倍更多患者完全恢复到正常/治疗前健康状态 [3] - 第8周时,ANX005组有2倍更多患者改善3分或以上 [3] - 第8周时,ANX005组有2.5倍更多患者能够跑步或更好 [3] 功能指标 - ANX005组患者较安慰剂组提前31天开始行走 [3] - ANX005组患者较安慰剂组提前28天脱离呼吸机 [3] 具有北美和欧洲基线特征的患者 - 第1周时,ANX005组患者肌力改善8.8分 [4][5] - 第8周时,ANX005组患者处于更好健康状态的可能性是安慰剂组的3倍 [5]

文章核心观点 - 医疗行业中有很多优秀的股票,投资者应该关注那些表现优于同行的公司 [1] - Annexon, Inc.(ANNX)是医疗行业中表现较好的公司之一 [1][4] - Avalo Therapeutics, Inc.(AVTX)也是医疗行业中表现较好的公司之一 [4][5] 公司总结 Annexon, Inc.(ANNX) - 隶属于医疗-生物医药和遗传学行业,该行业目前排名第83位 [6] - 今年以来公司股价上涨29.7%,优于医疗行业平均6.4%的涨幅 [4] - 过去90天内,公司全年盈利预测上调39.7%,显示分析师对公司前景看好 [3] Avalo Therapeutics, Inc.(AVTX) - 隶属于医疗-药品行业,该行业目前排名第83位 [7] - 今年以来公司股价上涨20.8% [4] - 过去3个月内,公司当年盈利预测上调94.5%,目前评级为买入 [5] 行业总结 - 医疗-生物医药和遗传学行业今年以来下跌2.4%,Annexon, Inc.表现优于行业 [6] - 医疗-药品行业今年以来下跌5.9%,Avalo Therapeutics, Inc.表现优于行业 [7] - 医疗行业整体表现较好,Annexon, Inc.和Avalo Therapeutics, Inc.有望继续保持良好表现 [8]

文章核心观点 - 公司正在进行一次公开发行,预计总募集资金为1.25亿美元[1][2] - 公司正在开发针对神经炎症性疾病的新型疗法,已取得了一些临床前验证[6] - 公司正在积极推进中晚期临床试验,希望尽快为患者带来新的治疗方案[6] 公司信息 - 公司名称为Annexon,是一家生物制药公司[6] - 公司专注于开发针对经典补体介导的神经炎症性疾病的新型疗法[6] - 公司的治疗候选药物旨在通过阻断上游C1q来阻止经典补体炎症级联反应[6] - 公司已在重症肌无力、亨廷顿病和地理性萎缩等疾病中取得了临床前验证[6] 融资信息 - 公司正在进行1.3亿股的公开发行,发行价格为每股6.25美元[1] - 此外还有700万份预付款认股权证以每股6.249美元的价格发行[1] - 预计总募集资金为1.25亿美元,扣除承销费用和其他发行费用后的净额[2] - 承销商包括摩根大通、富瑞、TD证券、美银美林和富国银行[3] - 发行完成后,承销商还有30天的超额配售选择权[2]

BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, ...

文章核心观点 - Annexon公司宣布其主要候选药物ANX005在治疗格林-巴利综合征(GBS)的III期临床试验中取得积极的结果 [1][2][3][4][5] - ANX005 30mg/kg剂量组在GBS-DS量表上显示出2.4倍的显著改善,同时在其他多个次要终点也优于安慰剂组 [2][3][4][5] - ANX005 30mg/kg剂量组患者在各项评估指标上较安慰剂组表现出更快的改善,显示该候选药物有望为GBS患者带来重要的临床获益 [5] - ANX005还能够较安慰剂组显著降低神经元损伤生物标志物NfL的水平 [6] - 虽然ANX005 75mg/kg剂量组在多个指标上优于安慰剂,但未能在主要终点GBS-DS上达到统计学显著性 [7][8] 公司相关 - Annexon公司将ANX005作为其三大旗舰开发项目之一,优先推进其在GBS适应症的开发 [14] - ANX005已获得FDA的快速通道和孤儿药资格认定,以及欧盟的孤儿药资格认定 [13] - 公司正在开展一项真实世界证据研究,以评估III期试验人群与国际GBS结局研究人群的可比性,预计2025年上半年获得结果 [11][12] 行业相关 - GBS是一种罕见的神经系统疾病,每年在美国和欧盟造成超过22,000例住院,目前尚无获批治疗方法,标准治疗为静脉注射免疫球蛋白 [9] - 基于ANX005 30mg/kg剂量的有利III期结果,公司认为一周的C1q抑制是GBS患者的最佳治疗窗口 [10]

Shares of Annexon, Inc. (ANNX) have gained 26.6% over the past four weeks to close the last trading session at $5.99, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14 indicates a potential upside of 133.7%.The mean estimate comprises six short-term price targets with a standard deviation of $8.37. While the lowest estimate of $7 indicates a 16.9% increase from the current pri ...

BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock. All of the shares are being offered by Annexon. In addition, Annexon expects to grant the underwriters a ...

BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock. All of the shares are being offered by Annexon. In addition, Annexon expects to grant the underwriters a ...

Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and web ...